The U.S. Court of Appeals for the Seventh Circuit agreed with a district court earlier this week that neither a settlement agreement between AbbVie and a number of generic biologics companies, nor the 132 patents owned by Abbvie covering its blockbuster drug, Humira, violate the Sherman Antitrust Act. This holding, which is significant in its own right, also has broader implications for patent-antitrust analysis.
Litigation
- How French and California Contract Law Would Interpret SEP Patent Owner Obligations Under the ETSI Licensing Declaration
- NYIPLA Tells Supremes IP Lawyers Need Attorney-Client Privilege for Dual-Purpose Communications
- A Guide to Disclosures in Delaware Patent Litigation in the Face of Pending Federal Circuit Review
- CAFC Expressly States Patentee Disclaimers During IPR are Not Binding on the PTAB’s Patentability Analysis
- Disruptive Startups Cannot Survive in a Post-AIA Patent Landscape
Recent Posts
- USPTO, Copyright Office Joint Study on NFTs Could Help Dispel Confusion About IP Ownership in Media Content Underlying Digital Assets
- How French and California Contract Law Would Interpret SEP Patent Owner Obligations Under the ETSI Licensing Declaration
- WIPO Report: China Sees Massive Surge in IP Filings Across the Board
- Other Barks & Bites for Friday, November 25: Seventh Circuit Nixes Publicity Claim Against Subscriber List Sale, Copyright Office and USPTO Announce NFT Study, and Alia Moses Takes Over as Chief Judge of Western Texas
- What IP Stakeholders are Giving Thanks for in 2022